| Bioactivity | DDO-02267 is a selective and lysine-targeting covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. DDO-02267 increases N6-methyladenosine (m6A) levels and targets the ALKBH5-AXL signaling axis. DDO-02267 can serve as a probe for investigating the biological function of mRNA demethylase[1]. |
| Target | ALKBH5: 0.49 μM, ALKBH3: 11.71 μM, FTO: 14.16 μM |
| CAS | 2919768-58-2 |
| Formula | C18H12N2O7S |
| Molar Mass | 400.36 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Fei WL, et al. Discovery of the salicylaldehyde-based compound DDO-02267 as a lysine-targeting covalent inhibitor of ALKBH5. Eur J Med Chem. 2024 Dec 23;284:117183. |
DDO-02267
CAS: 2919768-58-2 F: C18H12N2O7S W: 400.36
DDO-02267 is a selective and lysine-targeting covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. DDO-02267 in
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.